Xilio Development Inc (XLO) - Total Liabilities
Based on the latest financial reports, Xilio Development Inc (XLO) has total liabilities worth $141.79 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xilio Development Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Xilio Development Inc's total liabilities have evolved over time, based on quarterly financial data. See Xilio Development Inc (XLO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Xilio Development Inc Competitors by Total Liabilities
The table below lists competitors of Xilio Development Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metallic Minerals Corp
V:MMG
|
Canada | CA$861.37K |
|
dMY Squared Technology Group Inc
NYSE MKT:DMYY
|
USA | $27.18 Million |
|
SOOSAN INT Co. Ltd
KQ:050960
|
Korea | ₩3.92 Billion |
|
Cardlytics Inc
NASDAQ:CDLX
|
USA | $267.91 Million |
|
Ledlink Optics
TWO:5230
|
Taiwan | NT$1.02 Billion |
|
Speed Rabbit Pizza SA
PA:MLSRP
|
France | €1.66 Million |
|
Shriro Holdings Ltd
AU:SHM
|
Australia | AU$26.61 Million |
|
Cyclone Metals Ltd
AU:CLE
|
Australia | AU$1.18 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Xilio Development Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Xilio Development Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -17.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xilio Development Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xilio Development Inc (2019–2024)
The table below shows the annual total liabilities of Xilio Development Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $53.48 Million | +121.91% |
| 2023-12-31 | $24.10 Million | -28.10% |
| 2022-12-31 | $33.52 Million | -7.33% |
| 2021-12-31 | $36.17 Million | -13.06% |
| 2020-12-31 | $41.60 Million | +71.82% |
| 2019-12-31 | $24.21 Million | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which compr… Read more